Record FY26 performance, ahead of expectations. Revenue rose 17% to £270.2m, EBITDA reached £40.6m and the Group finished the year with £7.5m net cash. Dividend growth continued, up 4% YoY, reflecting confidence in cash generation.
Vaping transition executed well. Revenue increased 14.8% despite significant regulatory change, with Supreme successfully guiding customers from disposables to reusable pod systems. FY27 revenue will also reflect the accounting impact of the Vaping Products Duty, with no expected effect on profitability.
Drinks & Wellness becoming a key growth engine. Revenue grew 60% to £69.3m, supported by strong performances across sports nutrition, teas, soft drinks and weight management products. A full-year contribution from SlimFast underpins expectations for further growth in FY27.
Valuation remains undemanding despite positive outlook. Management reports a positive start to FY27, while recent acquisitions and manufacturing investment strengthen the platform for future growth. Our Fair Value remains 237p per share, implying c.35% potential upside on a rerating.
